Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIC versus MIC + MBEC-guided antibiotic selection for periprosthetic joint infection
2020-003444-80Phase 4Active
- Sponsor
- Sahlgrenska University Hospital
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rifampicin, fusidic acid, clindamycin, levofloxacin, linezolid and 2 more in periprosthetic joint infection (PJI) and Periprosthetic Hip Infection (PHI) (2 arms), sponsored by Sahlgrenska University Hospital. Started Aug 2020; status: active.
02
Drugs
rifampicinfusidic acidclindamycinlevofloxacinlinezolid
03
Conditions
periprosthetic joint infection (PJI)Periprosthetic Hip Infection (PHI)
Beyond the preview
Go deeper on 2020-003444-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003444-80.